1. What is the Chemxpert database?

Chemxpert database is a techno-commercial information platform developed and operated by Lifescience Intellipedia Pvt. Ltd. Our data provides valuable insights regarding sourcing, marketing, development, and regulatory functions for the entire Lifescience industry. The different industries covered by our data encompass APIs, FDFs, pharma intermediates, paints, dyes, polymers, biotechnology, biochemical, food additives, nutraceuticals, etc.

2. How can I subscribe to the Chemxpert database?

You can gain access to the Chemxpert database after subscribing to it by visiting this link: - https://chemxpert.com/pricing

3. How many countries' data is available on your portal?

The Chemxpert database covers more than 200 countries. We are working in the direction of expanding our data coverage in more countries.

4. What are the different sources you use for obtaining information?

The different sources we use for data collection are as follows: - • Primary researc • DMF, ANDA, & CEP list • Conferences, Exhibitions, & Tradeshow • Company annual reports • DMF, ANDA, & CEP list • Subject matter experts & KOL survey. Apart from these, our other valuable sources include application-wise manufacturers list, subscribed and non-subscribed databases, corporate partners, US FDA Orange book, publicly available sources, industry associates, national statistics, regulatory websites, etc. You can gain access to the Chemxpert database after subscribing to it by visiting this link: -https://chemxpert.com/sources

5. What is the expected time for account activation?

Your Chemxpert account will be activated instantly if the payment is made through our website. If you choose to use RTGS, NEFT, or IMPS systems for payment, your account will be activated within 24 hours.

18 Mar 2024
Admin
News Article

Salipro Biotech Receives European Patent

Salipro Biotech receives European patent entitled Production of Salipro particles

Overview

Swedish biotech company Salipro Biotech AB, a pioneering biotech company focusing on challenging drug targets for the discovery of next-generation therapeutics, announced that the European Patent Office (EPO) has granted a further patent in Salipro Biotech’s growing patent portfolio: European Patent EP 3 955 895 B1, entitled “Production of Salipro particles”. This patent covers processes related to the Salipro platform and represents a pivotal milestone that strengthens Salipro Biotech’s position as a key drug discovery platform holder for difficult drug targets such as GPCRs, ion channels and transporters.

Words from Leaders: Salipro Biotech

From CEO

“We are excited about this advancement on our intellectual property portfolio and the Salipro platform technology. This patent further solidifies our position by complementing our foundational and subsequent patents that have already been granted in many countries, including US, EU, China and Japan” says Jens Frauenfeld, CEO of Salipro Biotech. “This is another significant milestone for Salipro Biotech in building a robust patent portfolio that protects our unique platform technology and supports our commitment to make the undruggable druggable.”

From BDD

“We are actively forging more collaborations and licensing deals with leading pharmaceutical companies across a broad spectrum of complex drug targets.” says Peter Jahnmatz, Business Development Director at Salipro Biotech. “By further strengthening our robust patent portfolio, we enhance the value proposition for our partners in these collaborations and advance the development of next-generation therapeutics against previously inaccessible drug targets.”

Patent Aapproval Impacts

This patent is based on one of multiple patent filings of Salipro Biotech since 2016.

The grant of the European patent will provide Salipro Biotech’s unique platform technology with a broader protection, further strengthening its patent portfolio to address unmet medical needs and accelerate drug discovery programs against undruggable targets.

About Salipro Biotech AB

Salipro Biotech AB, headquartered in Stockholm, Sweden, is a privately held biotech company committed to unlocking challenging drug targets for the development of next-generation therapeutics.
With a fully owned intellectual property portfolio encompassing the Salipro platform technology, the company has established multiple research collaborations with leading pharmaceutical and biotech companies worldwide.

Let’s apply Data-Driven Pricing to Your APIs

Sick and tired of always wondering if you are being asked to pay the right price for your APIs? This empowers you with the answers you need to make the right decisions in the Global API market.

Chemxpert Database is one of the biggest and most comprehensive directories of pharma and chemicals, manufacturers, suppliers and information. Provided with current information on prices, demand and transactions, it gives you instant feedback on whether you are buying what is right and at the right time.

Start using market intelligence today and allow yourself to be in control in the API market.

Check it out today and make more informed sourcing decisions! Learn More!